Drug Development

Pack-Splitting to Improve Cost-Effectiveness of Oral Agents in Oncology

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

H&O What is the rationale behind the investigation of alternative dosing strategies of oral agents in oncology? RDH There are 2 key drivers of the […]

Ovarian Cancer

Highlights in Ovarian Cancer From the American Society of Clinical Oncology Annual Meeting

Thomas J. Herzog, MD

H&O First, let’s talk about secondary cytoreduction. Could you describe the DESKTOP III trial, and what makes it so important? TH The DESKTOP III trial, […]

Oncology

Workup of Anemia in Cancer

Sidharth Anand, MD, MBA, Aaron Burkenroad, MD, MS, and John Glaspy, MD, MPH

Abstract: Anemia is a common diagnosis in patients with cancer that may affect both quality of life and survival. Anemia in this patient population is […]

Ovarian Cancer

PARP Inhibition in Recurrent Ovarian Cancer

Kathleen N. Moore, MD, Bhavana Pothuri, MD, Bradley Monk, MD, and Robert L. Coleman, MD

Abstract: With the introduction of PARP inhibitors into frontline chemotherapy, with or without bevacizumab, the hope exists that more women may be spared a recurrence […]

Lymphoma

Duvelisib, a New PI3K Inhibitor for Lymphoid Malignancies

Nicole Lamanna, MD

H&O What type of drug is duvelisib? NL Duvelisib (Copiktra, Verastem Oncology) is an orally bioavailable, highly selective and potent small-molecule inhibitor of the delta […]

Hematology

New Paradigms for Anticoagulation in Pregnant Women With Inherited Thrombophilia

Deepa R. J. Arachchillage, MD, MRCP, FRCPath

H&O How common is inherited thrombophilia among women of childbearing age, and how often does it lead to venous thromboembolism? DA The term thrombophilia is […]

CLL

CLL In Focus

Devon Schuyler

CLL Linked to Elevated Risk for Second Cancers Even With BTK Inhibition Patients with chronic lymphocytic leukemia (CLL) are at increased risk for second cancers even […]

Letter From the Editor

Letter From the Editor: Our Relationship-Intensive Field

Daniel J. George, MD

I have heard many descriptors for the field of oncology over the years, but I must admit that when my resiliency coach referred to it as “relationship-intensive,” […]